1
With this in mind, it might seem that ROP screening and detection would be simple. Nothing could be further from the truth. To begin, advanced ROP can occur in a distribution of time extending from as early as 31 weeks' gestational age to as late as many weeks after the expected due date (40 weeks). Then there is the problem of infants who are back-transferred to nurseries that are less familiar with ROP or with the infant's ROP status. After some children are discharged, even with careful follow-up instructions, they fail to attend outpatient visits. Since prematurity is often a condition of lower socioeconomic status, the afflicted may have more difficulty gaining access to necessary health care. Last names change on discharge in many cases, complicating attempts to find lost infants. Retinopathy of prematurity often occurs after infants have survived and grown beyond other significant organ system diseases. Parents may not want to face yet another medical crisis.
Even when infants remain in a tertiary care facility during their ROP-vulnerable period, there are important obstacles to timely management of the disease. One of these obstacles is the timing and frequency of ROP examinations. In the Early Treatment for Retinopathy of Prematurity Study, infants were sometimes examined on a weekly basis or even every 2 to 4 days when more advanced disease was present. 2 Although the timing of these examinations was based on protocol requirements and issues, these protocol-mandated examinations are now making their way into clinical practice, placing an everincreasing burden on ophthalmologists who screen and treat ROP. 3 Whether infants benefit from increased screening frequency is unknown at this time, but there is little question that some infants have rapidly progressive disease and that a matter of a week in delay of treatment could make a difference in outcome.
Despite these many obstacles to optimal care for infants with ROP, physicians are under pressure to flawlessly manage infants with ROP. Understandably, there is no tolerance for any preventable blindness caused by this disease. Given the lifelong disability associated with congenital bilateral blindness, the goal of letting no child miss the opportunity to have necessary treatment is a laudable one. Unfortunately, the challenge of optimal management does not simply rest in the domain of identification of the disease and children vulnerable to its effects. Increasingly, ophthalmologists share responsibility for arranging follow-up examinations, finding lost patients, and even arranging transportation for some patients.
Against this backdrop, the importance of the work reported by Lö fqvist and colleagues 4 cannot be overemphasized. Ophthalmologists and their patients would benefit enormously from serum or physiological markers that indicate risk for ROP before ROP develops. Currently, algorithms for ROP screening emphasize birth weight and gestational age of the premature infant. 3 Screening examinations begin in a perfunctory fashion and are conducted until ROP regresses, never develops, or requires treatment. Every infant meeting birth weight and gestational-age guidelines should be screened and followed, even though fewer than 10% of these infants will need treatment for advanced ROP. Undoubtedly, thousands of examinations are performed to find those few infants who might benefit from treatment. The examinations are time-consuming; costly; somewhat uncomfortable; and, most importantly, often unnecessary. This latter observation, that examinations were needless in a given infant, can only be made in hindsight.
The RM-ROP2 program developed from the Cryotherapy for Retinopathy of Prematurity Study and used in the Early Treatment for Retinopathy of Prematurity Study for randomization purposes, can be used to assess risk for progression to blindness once prethreshold ROP develops. 5 By the time prethreshold disease is identified, the infant usually has had multiple examinations, perhaps has been transferred, or even has been discharged. Furthermore, the program does not apply to infants at risk for ROP at any point in their retinal vasculature development up to the time when prethreshold disease occurs. Here, prethreshold refers to an eye with any ROP in zone I; an eye with zone II ROP and at least 1 clock hour of stage 3 or plus disease; or both stage 3 and plus disease but fewer than the required number of clock hours to qualify as being threshold.
In their ingenious study, Lö fqvist and associates 4 show that monitoring postnatal factors of weight, insulin-like growth factor 1, and insulin-like growth factor binding protein 3 enhances clinicians' ability to detect patients who will require treatment for ROP. This work follows previous studies, which have indicated that at least 1 serum biomarker, insulin-like growth factor 1, fluctuates in synchrony with advancing ROP. 6 The beauty of this research is that the biomarkers under consideration are unlikely to simply be epiphenomenally associated with ROP. These proteins are probably causally involved in ROP development and progression and thus will be altered or expressed in accordance with presence or absence of ROP.
It is not necessary to identify every infant who will need treatment. Neonatologists, ophthalmologists, and their patients will benefit significantly from the knowledge that a given patient has a high likelihood of needing treatment for ROP. The risk status of an infant, if known weeks ahead of development of ROP, perforce will result in more careful monitoring and follow-up. Rather than presenting a family with information that follow-up is necessary to monitor ROP status, even though none is present, clinicians will be able to make the much stronger point that the family's child has a high probability of requiring treatment.
And it does not take much imagination to see how research on protein biomarkers for ROP will lead to new treatments. To date, clinicians have very little they can do to prevent ROP from occurring in premature infants. Armed with advanced knowledge of risk for ROP, it will be possible to study treatments that target putative molecular causes of the disease. In this regard, ophthalmologists share a great deal with other medical specialists in the desire to predict or find markers that indicate early disease presence. Witness the proliferation of proteomics approaches to cancer and the effort to find serum biomarkers for occult disease states. 7 Studies of novel treatments are also powered more effectively, and run more ethically, when the cohort consists of patients at particularly high risk for development of a disease. In the case of ROP treatment trials, the disease is uncommon and currently requires vast numbers of screened subjects to find a suitable cohort. Retinopathy of prematurity research would be less costly if enhanced with findings that allow early prediction of risk for severe disease.
Will serum markers and systemic factors ever take the place of ROP retinal screening examinations? Let's hope so. Future studies will center on detailed evaluation of serum of preterm infants, calibration of measures for serum biomarkers, and comparison of conventional screening approaches with novel approaches, such as detection of serum biomarkers of ROP. Prediction of ROP will ultimately lead to better treatments. We can all hope for the day when extensive retinal ablation is no longer required to prevent blindness from ROP. To reach this point will require more research such as that reported this month by Lö fqvist and colleagues. Until then, the presence or absence of biomarkers and physiological factors for ROP will complement that old standby, the ROP screening examination. 
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